SCHEMBL20600693

SCHEMBL20600693

Cn1cnc2ccc(-c3c(-c4cccc(F)n4)nc(N)c4nccn34)cc21

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 2/20 0.42
▸ ADORA2A P29274 7/20 0.39
▸ ADORA1 P30542 7/20 0.39
▸ ADORA2B P29275 4/20 0.39
▸ TGFBR1 P36897 3/20 0.39
▸ TGFBR2 P37173 2/20 0.39
▸ MAP3K20 Q9NYL2 2/20 0.39
▸ ALOX5AP P20292 1/20 0.36
▸ GRIA1 P42261 2/20 0.35
▸ CCNA2 P20248 2/20 0.34
▸ CDK2 P24941 2/20 0.34
▸ CSNK1E P49674 2/20 0.34
▸ CDK5 Q00535 2/20 0.34
▸ CDK5R1 Q15078 2/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CDK9 P50750 1/20 0.34
▸ HASPIN Q8TF76 1/20 0.34
▸ MAPK14 Q16539 1/20 0.34
▸ PRKCI P41743 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20600651 0.87 DYRK1A (0.44) DYRK1AADORA2AADORA1ADORA2BTGFBR1
SCHEMBL20600460 0.85 DYRK1A (0.45) DYRK1AADORA2AADORA1ADORA2BGRIA1
SCHEMBL20600738 0.85 GRIA1 (0.48) DYRK1AADORA2AADORA1ADORA2BGRIA1
SCHEMBL20600675 0.83 DYRK1A (0.44) DYRK1AADORA2AADORA1ADORA2BTGFBR1
SCHEMBL20600457 0.82 TGFBR1 (0.43) DYRK1AADORA2AADORA1TGFBR1TGFBR2
SCHEMBL20600758 0.82 DYRK1A (0.47) DYRK1AADORA2AADORA1ADORA2BGRIA1
SCHEMBL20600663 0.81 SMN1; SMN2 (0.41) ADORA2ATGFBR1ALOX5APGRIA1CCNA2
SCHEMBL20600497 0.80 DYRK1A (0.42) DYRK1AADORA2AADORA1ADORA2BTGFBR1
SCHEMBL20600682 0.80 DYRK1A (0.41) DYRK1AADORA2AADORA1ADORA2BGRIA1
SCHEMBL20600510 0.74 ADORA2A (0.42) ADORA2AADORA1TGFBR1TGFBR2GRIA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 — — US claimed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 — — EP claimed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 — — WO claimed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 — — US disclosed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 — — US disclosed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 — — EP disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 — — WO disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 DYRK1A 1125/4885ADORA2A 1/4885ADORA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback